Web NewDrugInformation.com

Adenosine Drug - Adenosine The trade name of the product as shown on the labeling. Dosage - INJECTABLE; INJECTION The product dosage form and route separated by a semi-colon. Active Ingredient(s) - Adenosine Multiple ingredients are in alphabetical order. Strength - 3MG/ML The potency of the active ingredient(s), Adenosine. May repeat for multiple part products. Applicant - BAXTER HLTHCARE The firm name holding legal responsibility for Adenosine. The firm name is condensed to a maximum twenty character unique string. New Drug Application (NDA) Number - 076500 The FDA assigned number to Adenosine. Format is nnnnnn. Product Number - 001 The FDA assigned number to identify Adenosine. Each strength is a separate product. May repeat for multiple part products. Format is nnn. Therapeutic Equivalence (TE) Code - AP The TE Code indicates the therapeutic equivalence rating of generic to innovator Rx products. Approval Date - Jun 16, 2004 The date Adenosine was approved as stated in the FDA approval letter to the applicant. The format is Mmm dd, yyyy. Products approved prior to the January 1, 1982 contain the phrase: "Approved prior to Jan 1, 1982". Reference Listed Drug (RLD) - No The pioneer or innovator of Adenosine. The RLD identifies the product Abbreviated New Drug Applications (ANDA) use as a reference. Format is Yes or No. Type - RX The group or category of approved drugs Adenosine is in. Format is RX, OTC, DISCN. Applicant Full Name - Baxter Healthcare Corp The full name of the firm holding legal responsibility for the new application of Adenosine. Adenosine Adenosine 3mg/ml Injectable; Injection Zovirax Eq 1gm Base/vial Injectable; Injection Zovirax Eq 250mg Base/vial Injectable; Injection Zovirax Eq 500mg Base/vial Injectable; Injection Differin 0.1% Cream; Topical Differin 0.1% Gel; Topical Differin 0.1% Solution; Topical Hepsera 10mg Tablet; Oral Adenocard 3mg/ml Injectable; Injection Adenoscan 3mg/ml Injectable; Injection NewDrugInformation